Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 15/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23010843 | 0.83 | HRH4 (0.56) | HRH4HRH3MEN1KMT2A | |
| SCHEMBL6645486 | 0.80 | HRH4 (0.57) | HRH4HRH3HRH1POLBHTR3A | |
| SCHEMBL6381282 | 0.75 | HRH4 (0.68) | HRH4HRH3HRH1POLB | |
| Jnj-7777120 SCHEMBL186434 | 0.73 | HRH4 (1.00) | HRH4HRH3HRH1KMT2A | |
| Jnj-7777120 SCHEMBL29381532 | 0.73 | HRH4 (1.00) | HRH4HRH3HRH1KMT2A | |
| SCHEMBL16599078 | 0.72 | DRD2 (0.50) | KMT2A | |
| SCHEMBL16598765 | 0.70 | MEN1 (0.46) | POLBMEN1KMT2A | |
| SCHEMBL14046591 | 0.70 | NPC1 (0.74) | HRH4HRH3HTR3AMEN1KMT2A | |
| SCHEMBL605145 | 0.69 | HRH4 (1.00) | HRH4HRH3HRH1HTR3AMEN1 | |
| SCHEMBL6645619 | 0.68 | PDGFRB (0.47) | HRH4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.